Amycretin, MariTide & Pemvidutide — EU research guide.

Why group these three?

Amycretin, MariTide and Pemvidutide are three of the most-watched next-generation obesity candidates, each chosen to illustrate a different mechanistic direction the field is taking beyond the first-wave single GLP-1 agonists. None is approved as of mid-2026; all are investigational drugs owned by individual developers. This entry is a factual reference to where each sits, not an endorsement or a sourcing guide.

Amycretin (Novo Nordisk)

Amycretin is a unimolecular agonist of both the GLP-1 and amylin receptors — a single molecule combining the two mechanisms that CagriSema achieves with two separate peptides. It is being developed in both subcutaneous and oral forms. Early-phase data have been notably strong (subcutaneous figures of up to roughly 22–24% weight loss in early studies have been reported), and a Phase 2 trial in type 2 diabetes reported statistically significant weight loss and HbA1c reduction. Phase 3 development is planned.

MariTide (maridebart cafraglutide, Amgen)

MariTide (formerly AMG 133) is structurally unusual: a peptide-antibody conjugate that combines GLP-1 receptor agonism with GIP receptor antagonism (the opposite GIP direction to tirzepatide). Its ~21-day half-life supports once-monthly — or less frequent — dosing. The Phase 2 trial (published in NEJM, 2025) reported up to ~20% weight loss at 52 weeks in obesity without diabetes, and up to ~17% with type 2 diabetes, without a clear plateau. The Phase 3 MARITIME programme is underway.

Pemvidutide (Altimmune)

Pemvidutide is a dual GLP-1 / glucagon receptor agonist — the glucagon arm intended to add energy expenditure and liver-fat benefit. Phase 2 data reported around ~15.6% weight loss and a high rate of MASH (fatty-liver disease) resolution, with no dose titration required. Its dual interest is therefore both obesity and metabolic liver disease.

EU legal status

All three are investigational pharmaceuticals, not approved in the EU and not generic research peptides. There is no legitimate research-supply route, and gray-market material claiming to be any of them cannot be assumed authentic. They are included here for mechanistic and pipeline context only.